Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease (NCT05785624).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:34 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Public evidence indicates a negative trial outcome. Roche said the Phase 2 IPF/SSc-ILD vixarelimab study failed a futility review and was unlikely to achieve its efficacy objectives, and Roche subsequently removed RG6536 from Phase II in its Jan. 29, 2026 pipeline update.

Sources
Web Searchfiercebiotech.com1/29/26
Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout

Roche said the vixarelimab Phase 2 study in idiopathic pulmonary fibrosis/systemic sclerosis-associated ILD hit a futility analysis and was unlikely to achieve its efficacy objectives; no new safety signals were identified.

View source
Sponsorassets.roche.com1/29/26
Roche Group development pipeline — Q4 2025 update

Roche’s Jan. 29, 2026 pipeline update lists RG6536 vixarelimab for IPF/SSc-ILD under 'Removed from phase II,' consistent with discontinuation after the negative futility review.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public evidence indicates a negative trial outcome. Roche said the Phase 2 IPF/SSc-ILD vixarelimab study failed a futility review and was unlikely to achieve its efficacy objectives, and Roche subsequently removed RG6536 from Phase II in its Jan. 29, 2026 pipeline update.

Found Apr 1, 2026, 6:34 PMOutcome date Jan 29, 2026, 12:00 AMReviewed Apr 1, 2026, 6:36 PM
Web Searchfiercebiotech.comJan 29, 2026, 6:29 AM
Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout
Roche said the vixarelimab Phase 2 study in idiopathic pulmonary fibrosis/systemic sclerosis-associated ILD hit a futility analysis and was unlikely to achieve its efficacy objectives; no new safety signals were identified.
Sponsorassets.roche.comJan 29, 2026, 12:00 AM
Roche Group development pipeline — Q4 2025 update
Roche’s Jan. 29, 2026 pipeline update lists RG6536 vixarelimab for IPF/SSc-ILD under 'Removed from phase II,' consistent with discontinuation after the negative futility review.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 6:36 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)95% confidenceReviewed Apr 1, 2026, 6:36 PM

Public evidence indicates a negative trial outcome. Roche said the Phase 2 IPF/SSc-ILD vixarelimab study failed a futility review and was unlikely to achieve its efficacy objectives, and Roche subsequently removed RG6536 from Phase II in its Jan. 29, 2026 pipeline update.